Eli Lilly announced that its breakthrough drug, Mounjaro (tirzepatide), has received marketing authorization from India’s ...

Lilly may also pay as much as $300 million more if Verve’s top drug hits certain research milestones. That would bring the total deal to $1.3 billion, The WSJ reported.

WEDNESDAY, June 18, 2025 (HealthDay News) — Drugmaker Eli Lilly plans to buy Verve Therapeutics, a gene-editing startup, for about $1 billion upfront. The deal gives Lilly a potential new ...

Key Takeaways Eli Lilly will acquire Verve for roughly $1 billion Verve is developing a one-time gene-editing treatment for heart disease The company's lead drug, Verve-102, targets a gene linked ...

Indianapolis-based Eli Lilly announced its definitive agreement to acquire Verge, a gene-editing startup, for up to $1.3 billion at $10.50 a share -- a premium of 67.5% at last closing -- with the ...

The stock is up 19% in the past year. Lilly shares edged 1% lower, to $799.44, in premarket trading and are down 9.4% over the past year. Verve is developing a pipeline of gene-editing medicines.

(Reuters) -Eli Lilly will acquire gene-editing startup Verve Therapeutics for up to $1.3 billion, the companies said on Tuesday, accelerating a push into experimental cardiovascular therapies. The ...

Further assessment of data for the 72-week study of adults without diabetes showed that the percent who saw ≥25% body weight loss (57-58 lbs) was 15.3% for 5 mg, 32.3% for 10 mg, 36.2% for 15 mg ...

Meanwhile, Bloomberg reported that Eli Lilly saw a 60% jump in sales of its weight-loss and diabetes drug Mounjaro in India in May compared to April, marking its second full month on the Indian ...

The Japanese biotech behind Eli Lilly’s new blockbuster obesity pill believes it could be used with an anti-muscle wasting drug it has developed to create a new standard of patient care for ...

Eli Lilly is the most likely healthcare stock to reach a $1 trillion valuation, and I believe it could hit that plateau by 2027. Eli Lilly's stock has surged close to 400% in five years.

Eli Lilly stock is a no-brainer buy right now For Eli Lilly to reach a $1 trillion market cap within the next couple of years, it would need to rise by more than 50% from where it is today.